• Paysign outlined $106.5 million-$110.5 million revenue guidance for FY 2026, implying 30%-35% growth.
• Adjusted EBITDA outlook set at $30 million-$33 million, implying 51%-66% growth and a 27%-31% margin.
• FY 2025 revenue rose 40.5% to $82 million; adjusted EBITDA jumped 107.3% to $19.9 million; gross margin was 59.4%.
• Patient affordability revenue reached $40.9 million on a trailing basis, up 116.9% year over year; 141 active pharma programs reported.
• Plasma business cited about 45.5% U.S. market share, serving 554 donation centers with 8.4 million cardholders on the platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Paysign Inc. published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained therein.